Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Non-cash Items: 2018-2025

Historic Non-cash Items for Whitehawk Therapeutics (WHWK) over the last 4 years, with Sep 2025 value amounting to $3.2 million.

  • Whitehawk Therapeutics' Non-cash Items was N/A to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year change of. This contributed to the annual value of $10.0 million for FY2021, which is 1881.58% up from last year.
  • Whitehawk Therapeutics' Non-cash Items amounted to $3.2 million in Q3 2025, which was up 607.42% from $459,000 recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Non-cash Items ranged from a high of $10.0 million in Q4 2021 and a low of $459,000 during Q2 2025.
  • Over the past 1 years, Whitehawk Therapeutics' median Non-cash Items value was $1.9 million (recorded in 2025), while the average stood at $1.9 million.
  • The largest annual percentage gain for Whitehawk Therapeutics' Non-cash Items in the last 5 years was 1,881.58% (2021), contrasted with its biggest fall of 81.20% (2021).
  • Over the past 3 years, Whitehawk Therapeutics' Non-cash Items (Quarterly) stood at $10.0 million in 2021, then spiked by 114.49% to $5.6 million in 2022, then reached $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $459,000 for Q2 2025, and $5.6 million during Q1 2022.